reputation of the life sciences
industry. The industry is actually
incredibly respected in Washington on both sides of the aisle.
Now, sure, are there people who
are just detractors who you sort
of hate at any cost? Yes. But that’s
not the majority sentiment either
among Democrats or Republicans
on the Hill. The pharma industry
is highly valued. These are some
of the best jobs in the United
States. It is an economic engine of
international trade for the United
States. It is an intellectual property
repository for the United States.
It’s the crown jewel. Any country
on earth would like to have the
biopharmaceutical industry that
we have here in the US. Okay?
And policymakers, at least behind
closed doors, understand and
He was most enthusiastic about
the fact that we are at the begin-
ning of a golden age in pharma-
ceuticals. This is largely due to the
success of the Human Genome
Project, which greatly increased
our understanding of the molecu-
lar nature of disease, and enhanced
our ability to custom-design mol-
ecules for targeted conditions.
“This is revolutionary. We’re seeing this come out of the pipeline
right now. We are changing the
nature of disease in the world
today. And policymakers get that.
It is an unbelievably exciting time
to be in this industry. It’s an even
more exciting time to be a patient
suffering from one of these debili-
tating diseases because you are go-
ing to see, over the next decade, a
change in the expectation of what
it means to live with some of the
world’s most debilitating diseases.
And that is what we all got into
this business for.
“I really do believe this is the fruits
of that work. And it’s just the
Alex Azar served President George
W. Bush as Deputy Secretary of Health
and Human Services, and went on to
hold several positions at Eli Lilly & Co.,
including president of Lilly USA, LLC from
2007 to 2017. He is currently chairman
and founder of Seraphim Strategies, LLC,
which provides strategic consulting on the
biopharmaceutical and health insurance
industries. He consults with the Trump administration on